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Helicobacter pylori infection is an important cause of chronic active gastritis, peptic ulcer 
disease and gastric cancer. The current treatment against H. pylori, consisting of a 
combination of a proton pump inhibitor and two different antibiotics, is effective but has 
several drawbacks such as high cost and increased risk of antibiotic resistance. A vaccine 
against H. pylori would therefore be an attractive alternative or complement to the current 
treatment. Using an established mouse model of H. pylori infection, we have studied the 
induction of innate immune responses by CpG oligodeoxynucleotides (ODN). In addition, we 
sought to identify induction of protection as well as immune responses that are related to 
vaccine induced protection against II. pylori. We also wanted to identify candidate antigens 
that could be used in a therapeutic II pylori vaccine. 
Oral administration of CpG ODN induced local production of chemokines in the gastric 
mucosa and also resulted in significant protection, i.e. reduction in the bacterial load in the 
stomachs of H. pylori infected mice. 
To evaluate protection induced by therapeutic immunization and protective immune 
mechanisms that can be related to protection against H. pylori, vaccination strategies were 
used that previously had been shown to be effective for prophylactic immunization. Oral 
therapeutic immunization with II. pylori lysate and cholera toxin (CT) as adjuvant induced 
significant protection, whereas intraperitoneal immunization using lysate and Alum did not 
induce any such protection. The reduction in bacterial load was related to increased mucosal 
H. pylori-specific Thl-tilted CD4+ T cell responses and to specific IgA levels in saponin-
extracted stomach tissue. 
II. pylori adhesin A (HpaA) is a surface located H. py/on'-specific protein present in all strains 
tested. To evaluate whether HpaA is important for colonization in mice, an isogenic mutant of 
strain SSI lacking a functional hpaA gene was constructed. To ascertain that disruption of the 
hpaA gene had not introduced any second site mutations or caused any polar effects on its 
downstream genes, the protein expression patterns of the mutant and the wild-type strain were 
compared by proteomic approaches. Apart from expression of HpaA, only some minor 
differences were seen between the two strains and so the mutant strain was tested for its 
colonizing ability in mice. While inoculation with wild-type II. pylori resulted in heavily 
infected mice, no bacteria could be detected in the stomachs of mice infected with the 
isogenic HpaA mutant, suggesting that HpaA is essential for colonization of H. pylori in mice. 
Next, we evaluated the capacity of HpaA to induce protection when administered 
therapeutically to infected mice. We found that oral immunization with HpaA and CT induced 
significant protection, which was even more pronounced when a combination of HpaA, 
urease and CT was used. Similar to the oral immunization with lysate, this protection was also 
accompanied by antigen-specific mucosal CD4+ T cell responses with a Thl profile as well as 
by IgA responses in the stomach. 
In conclusion, we have shown that mucosal IgA and CD4+ T cell responses are related to 
protection against H. pylori after therapeutic immunization in mice. In addition, HpaA is a 
colonization factor for II. pylori in mice and a promising candidate antigen for a therapeutic 
vaccine. 
Keywords: Helicobacter pylori, Cholera toxin, CpG ODN, CD4+ T cells, IgA, Therapeutic 
Immunization, HpaA 
ISBN: 91-628-6796-2 
Experimental Studies of Helicobacter pylori Immunization; 
Identification of Protective Immune Responses 
and Vaccine Candidate Antigens 
Johanna Nyström 
Institute of Biomedicine 
Department of Microbiology and Immunology 
Göteborg University 
2006 
ISBN 91-628-6796-2 
© 2006 Johanna Nyström 
Drawing of H. pylori by Helena Carlsson 
Printed by Vasastadens Bokbinderi AB, 
Göteborg, Sweden 2005 
- 2 -
If you only walk in good weather you will 
never reach your destination 
Anonymous 
- 3  -
'ÄS:ÄV#'. 
• • • . -  :  •  ;  
V y - .!•: : ; 
"
!  
'  - •  "  '  • •  '  .  • :  • •  '  •'  '  
•  ;  : .  ;  
v;.^ . 
• ;i ' 
:  • :  
••V-- .ot -• •• :•• .: • 
:'.. . v:v .. ' ' 
'••M ' '' 
"" ' 
' - I . ? -
• 
-:.- :i^ '! ^  v; v : i -'il ; ïï (/: ;^ v >1; al>K" 
• 
;; * ' •' • ' 
: • 
r'y^l 
•'.. .' . . . . '• > ./ : .... 
;  -  •  i .  v . ' • . .  
- Kt>; 
'•-: ' . :v r>^ >::":. ?..S- • öiafiSe. 
. ...'. . .: '. ' ' ' ' ' 
, . . . •  ^  -  • ;  :  , : ;  
v:,;'. .• ;  .• • •". ;  .  • -;•... .' 
: ;
..V....::;'. ; 
..'.'• Y " '< " ^V. ..••• •;• •• -  •. • V  : ; .. 
- ' •'' ' . .• ' ' ' ' 
' ' ' ..' ""'-.'V" " 
;:..'>=rv»s" 
ï gr ;\v 
ÂilïififiS^  
. 
•  " • " : : • " • " .  •  /  •  . •  :  :  • :  • .  
x :  •.•.••';-• •:: x  Y . 
' ' .. V ' ' ' • 
, :. '.....".. .... . : . 
•• . 
•Bm VA y$£s* 
-  • • ' V ' . - Ä - J Ï Ï - . . ;  - y - ; : ' :  
. 4 .  
SifÄ? 
• . • • • • • •  
......sia*,.,^  
ABSTRACT 
Helicobacter pylori infection is an important cause of chronic active gastritis, peptic ulcer 
disease and gastric cancer. The current treatment against H. pylori, consisting of a 
combination of a proton pump inhibitor and two different antibiotics, is effective but has 
several drawbacks such as high cost and increased risk of antibiotic resistance. A vaccine 
against H. pylori would therefore be an attractive alternative or complement to the current 
treatment. Using an established mouse model of H. pylori infection, we have studied the 
induction of innate immune responses by oral administration of CpG oligodeoxynucleotides 
(ODN). In addition, we sought to identify induction of protection as well as immune 
responses that are related to vaccine induced protection against H. pylori. We also wanted to 
identify candidate antigens that could be used in a therapeutic H. pylori vaccine. 
Oral administration of CpG ODN induced local production of chemokines in the gastric 
mucosa and also resulted in protection against H. pylori, i.e. significant reduction in the 
bacterial load in the stomachs of H. pylori infected mice. The protection correlated with the 
extent of gastric inflammation and chemokine production. 
To evaluate protection induced by therapeutic immunization and protective immune 
mechanisms that can be related to protection against H. pylori, vaccination strategies were 
used that previously had been shown to be effective for prophylactic immunization. Oral 
therapeutic immunization with H. pylori lysate and cholera toxin (CT) as adjuvant induced 
significant protection, whereas intraperitoneal immunization using lysate and Alum did not 
induce any such protection. The reduction in bacterial load was related to increased mucosal 
H. pylori-specific Thl-tilted CD4+ T cell responses and to specific IgA levels in saponin-
extracted stomach tissue. 
H. pylori adhesin A (HpaA) is a surface located H. pylori-specific protein present in all strains 
tested. To evaluate whether HpaA is important for colonization in mice, an isogenic mutant 
of s train SSI lacking a functional hpaA gene was constructed. To ascertain that disruption of 
the hpaA gene had not introduced any second site mutations or caused any polar effects on 
its downstream genes, the protein expression patterns of the mutant and the wild-type 
strains were compared by proteomic approaches. Apart from expression of HpaA, only some 
minor differences were seen between the two strains and so the mutant strain was tested for 
its colonizing ability in mice. While inoculation with wild-type H. pylori resulted in heavily 
infected mice, no bacteria could be detected in the stomachs of mice infected with the 
isogenic HpaA mutant, suggesting that HpaA is essential for colonization of H. pylori in 
mice. Next, we evaluated the capacity of HpaA to induce protection when administered 
therapeutically to infected mice. We found that oral immunization with HpaA and CT 
induced significant protection, which was even more pronounced when a combination of 
HpaA, urease and CT was used. Similar to the oral immunization with lysate, this protection 
was also accompanied by antigen-specific mucosal CD4+ T cell responses with a Thl profile 
as well as by IgA responses in the stomach. 
In conclusion, we have shown that mucosal IgA and CD4+ T cell responses are related to 
protection against H. pylori after therapeutic immunization in mice. In addition, HpaA is a 
colonization factor for H. pylori in mice and a promising candidate antigen for a therapeutic 
vaccine. 
Keywords: Helicobacter pylori, Cholera toxin, CpG ODN, CD4+ T cells, IgA, Therapeutic 
Immunization, HpaA 
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ABBREVIATIONS 
1D-GE One-dimensional gel electrophoresis 
2D-GE Two-dimensional gel electrophoresis 
APC Antigen presenting cell 
BabA Blood group binding adhesin A 
CFU Colony forming units 
CpG ODN Cytidine-phosphate-Guanosine oligodeoxynucleotide 
CT Cholera toxin 
CTB Cholera toxin B subunit 
DC Dendritic cell 
DIGE Differential in-gel electrophoresis 
ELISA Enzyme-linked immunosorbent assay 
FT-ICR Fourier transform-ion cyclotrone resonance 
GM Geometric mean 
HpaA Helicobacter pylori adhesin A 
IFN-y Interferon- y 
Ig Immunoglobulin 
IL Interleukin 
Ip Intraperitoneal 
IP-10 Gamma interferon-inducible protein 10 
Le Lewis antigen 
LPS Lipopolysaccharide 
LT E. coli heat labile enterotoxin 
MHC Major histocompatibility complex 
MIP-la/ß Macrophage inflammatory protein 1 a/p 
MLN Mesenteric lymph node 
MS Mass spectrometry 
OMP Outer membrane protein 
RANTES Regulated on activation, normal T cell expressed and 
secreted 
RT-PCR Reverse Transcriptase Polymerase Chain Reaction 
SSI Sydney strain 1 
Th T helper 
TLR Toll like receptor 
TNF-a Tumor Necrosis Factor -a 
VacA Vacuolating cytotoxin A 
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INTRODUCTION 
HISTORY 
For a long time, the human stomach was considered to be a sterile organ where no 
microorganisms could live due to the harsh acidic conditions. However, 1982 Warren 
and Marshall were able to culture Helicobacter pylori bacteria from patients 
undergoing gastroscopy and found that the bacteria were present in patients with 
active chronic gastritis, duodenal ulcer or gastric ulcer (1). They were later awarded 
the Nobel Prize (in 2005) for their discovery of H. pylori and its role in gastritis and 
peptic ulcer disease. The fact that it was a bacterium that caused peptic ulcer and not 
stress, spicy foods, or other factors was a surprise to the scientific community and 
Warren and Marshall had a hard time overturning the prevailing dogma. Marshall 
later fulfilled Koch's postulate by swallowing a solution of the bacteria, thus 
infecting himself and developed acute gastritis (2). This did not convince the medical 
world either, and it was not until the early 1990s that it was recognized that H. pylori 
causes gastric ulcer. 
HELICOBACTER PYLORI 
The gram-negative bacterium H. pylori infects the gastric mucosa of more than half of 
the world's population, making it one of the most common bacterial infections. The 
prevalence in developing countries can be as high as 80-90%, whereas it is lower in 
developed countries, ranging between 10-50% (3). While H. pylori prevalence 
decreases in the developed countries (e.g. in North America and Western Europe) no 
such decrease has been detected in the developing world (4). The prevalence of 
infection is strongly associated with low socioeconomic status, overcrowding and 
poor hygiene (4-6). The infection is generally believed to be acquired during 
childhood (7). Although the mode of transmission has not been completely 
- 9 -
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elucidated, epidemiological studies suggest that H. pylori is primarily spread by the 
fecal-oral or oral-oral routes (8). 
Colonization by H. -pylori is restricted to the human gastric mucosal cells in the 
stomach as well as areas of g astric metaplasia in the duodenum. The majority of the 
infecting H. pylori bacteria (90 %) are free-living within the secreted mucus in the 
stomach. However, a minority of H. pylori cells adheres to gastric epithelial cells (9). 
It has also been suggested that a small number might invade epithelial cells (10) even 
though this remains controversial. The colonization is thought to be a dynamic 
process in which the bacterium continuously attaches and detaches from the 
epithelial cells. 
H. pylori can colonize both the antrum and the more acidic corpus parts of the 
stomach. All H. pylori infected individuals develop chronic active gastritis, which is 
characterized by recruitment of immune cells and epithelial cell damage. Despite this 
gastritis, most infected individuals remain asymptomatic. However, 15% of the H. 
pylori infected individuals develop duodenal ulcer and about 2% gastric 
adenocarcinoma (11). In fact, H. pylori was designated a class 1 carcinogen in 1994 by 
the World Health Organization (WHO). 
Why do some individuals remain asymptomatic and some develop disease? 
Similarly to many infectious diseases, the outcome of infection depends on both 
environmental, host and microbial factors. 
The current treatment against H. pylori infection consists of a combination therapy 
with two different antibiotics together with a proton-pump inhibitor, which in most 
cases results in successful eradication of the bacteria and healing of ulcers (12). 
However, there are some major drawbacks with such therapy including high cost, 
poor patient compliance and increased risk of developing antibiotic resistance, 
making it unsuitable for use e.g. in the developing world (13, 14). Furthermore, such 
treatment does not protect against reinfections, which frequently occur in areas with 
high prevalence of H. pylori (15-17). A vaccine would therefore be a suitable 
alternative for control of II. pylori. It should preferably work on two different levels, 
i.e. to result in a decreased risk of developing H. pylori-associated disease for an 
individual, and to decrease the risk of i nfection at a population level. A prophylactic 
vaccine would be given before an individual becomes infected with H. pylori, i.e. in 
children. A therapeutic vaccination would primarily be given to those that have 
developed H. pylori associated diseases. In addition, because chronic H. pylori 
infection, even in the absence of symptoms, is a risk factor for development of 
adenocarcinoma (18), vaccination of asymptomatic carriers may be justified. 
Furthermore, a therapeutic vaccine would confer protection against reinfection. 
-  1 0 -
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VIRULENCE FACTORS FOR COLONIZATION AND INFLAMMATION 
In order to establish and maintain infection, H. pylori expresses a variety of different 
types of virulence factors, to enable survival and colonization in the stomach. These 
factors include the urease enzyme which creates a favourable environment for H. 
pylori in the acidic stomach, the flagellae which provides motility, and different 
adhesion factors, e.g. BabA and SabA, which enable H. pylori to adhere to surface 
mucosal cells and to components of the mucus layer and thereby avoid bacterial 
shedding. Some strains are more pathogenic and are associated with more severe 
disease outcome, due to the virulence factors they possess (Table 1 and Fig. 1). 
HpaA 
The H. pylori adhesin A (HpaA) is a lipoprotein (19) initially described as 
a sialic acid binding adhesin, but supportive evidence for its adhesion capacity is still 
lacking (19, 20). HpaA is surface-located (21-23) but has been found to be expressed 
in even higher quantities in the inner membrane of II. pylori and is also present in 
the cytoplasm (E. Carlsohn, personal communication, 19). H. pylori infected 
individuals mount serum antibodies, but only low levels of mucosal IgA antibodies 
against HpaA (24, 25). The expression of the HpaA protein is highly conserved 
among H. pylori isolates (24, 26). Indeed, we have not identified any H. pylori strain 
lacking this lipoprotein among several hundred isolates tested. Furthermore, 
genomic studies (27, 28) do not show any significant sequence homologies or 
similarities of HpaA with other known proteins. Taken together, this makes HpaA a 
putative candidate vaccine antigen against H. pylori infection. 
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VACCINATION AGAINST H. PYLORI 
Vaccination against H. pylori would be an effective and cost-effective means of 
controlling H. pylori disease. Because H. pylori infection by itself does not lead to 
spontaneous eradication but rather stays chronic for life, it is tempting to conclude 
that the immune responses induced by the natural infection is not sufficient per se to 
eradicate H. pylori. Also, vaccination with II. pylori antigens alone has not conferred 
any protective immune responses against H. pylori in experimental studies (46).Thus, 
the effectiveness of a vaccine depends on the development of ari appropriate antigen 
formulation that includes an immunostimulatory adjuvant. 
Adjuvants 
The only approved adjuvants for human use are aluminium salts (aluminium 
phosphate and aluminium hydroxide), generally called alum, and the new MF59 
adjuvant, a squalene oil-in-water emulsion (47). The mechanism by which alum 
enhances the immune response is not completely known, but it has been suggested 
that it works by activating antigen presenting cells (APC) e.g. dendritic cells (DC), 
stimulate the complement system and induce chemokine production (48). Although 
alum has a good safety record, it is a weak adjuvant for induction of antibodies and 
cell-mediated immunity against subunit proteins (49). In addition, there are 
associations between alum and allergic reactions (49). Also, both MF59 and alum are 
included in parenteral vaccines and are generally not suitable for induction of 
mucosal immunity. Thus, there is an urgent need for a safe and effective mucosal 
adjuvant for human use. 
Mucosal adjuvants 
The primary reason for using mucosal vaccination is to induce an immune response 
at the site of infection i.e. at the mucosal surface, because most infectious agents enter 
through or colonize mucosal surfaces. This is true for H. pylori, which is not an 
invasive bacterium. 
Cholera toxin (CT1 and CT derivatives 
Cholera toxin (CT), which is responsible for the severe cholera diarrhea in humans 
(50), has been extensively used as a potent mucosal adjuvant in several animal 
studies (51-54). The CT holotoxin consists of two subunits: an enzymatically 
active/toxigenic A subunit (CTA), and a pentameric B subunit (CTB), which is 
responsible for binding of CT to the ganglioside GM1 receptor, a glycosphingolipid 
found on the surface of all nucleated cells, including mucosal epithelial cells (55). 
Binding to the epithelial cell enables CTA to enter the cytosol, where it ADP 
ribosylates the stimulatory oc-subunit of the GTP-binding protein Gs. This leads to 
activation of adenylate cyclase which results in increased intracellular cAMP levels in 
the cell (56, 57). 
Oral administration of CT increases the permeability of epithelial cells (58), which 
can lead to increased uptake of coadministered antigen. However, the most 
-  14 -
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important contributors to immunity induced by CT are believed to be those leading 
to increased antigen presentation by DC, B cells and macrophages. Indeed, CT 
upregulates the expression of MHC molecules and costimulatory molecules e.g. 
CD80/B7.1 and CD86/B7.2 as well as chemokine receptors on both murine and 
human APC (59, 60). 
CT activates the cellular immune responses to coadministered antigens and increases 
the induction of mucosal IgA as well as CD4+ and Class I cytotoxic T cell responses 
(61-63). However, the inherent toxicity of CT precludes its use as an oral adjuvant in 
humans (64). Indeed, it has been shown that administration of as little as 5 Lig CT to 
human volunteers induces significant diarrhea and that 25 |ig may give rise to 20 liter 
watery diarrhea (65). In contrast, mice may be given 10 jj,g CT orally without any 
diarrhea. The nontoxic CTB subunit is a poor adjuvant for induction of mucosal 
immune responses in mice when given via the oral route, but its adjuvanticity is 
increased when administered intranasally (66, 67). Another approach to decrease the 
toxicity of CT but to retain its adjuvanticity has been to link the enzymatically active 
CTA subunit to the cell binding moiety of Staphylococcus aureus protein A (CTA1-
DD). In addition, by combining CTA1-DD with immune stimulating complexes 
(ISCOMS), systemic and mucosal T helper (Th)l and Th2 responses are shown after 
oral and intranasal administration (68). 
LT and LT derived adjuvants 
E. coli heat labile enterotoxin (LT) has 80% homology with CT in the primary 
structure and they have super-imposable tertiary structures (69, 70). Similarly to CT, 
LT has been used as a mucosal adjuvant in many animal studies but is too toxic for 
human use (71, 72). 
One approach to circumvent the toxicity of LT has been to construct mutants in the 
active site of the A subunit, thus inhibiting the ADP ribosylating activity. In the 
adjuvant LTK63 a serine-to-lysine substitution in position 63 of the A subunit has 
been introduced. This adjuvant has no enzymatic activity or toxicity in vivo or in 
vitro, but maintains all the biological properties such as receptor binding (73). LTK63 
is a potent mucosal adjuvant, even though its adjuvant activity is lower than that of 
LT. In addition, LTK63 exhibits better adjuvanticity than LTB showing that even 
though the A subunit is enzymatically inactive, it plays an important role for the 
induction of immune responses. Furthermore, immunization using H. -pylori antigens 
and LTK63 has conferred protection against H. pylori in mice (40, 74) and LTK63 has 
been tested in humans as a mucosal adjuvant for an influenza vaccine (75). 
Another class of detoxified toxin adjuvants is LTR72 (where alanin has been changed 
to arginine). This adjuvants maintains 1% of the wild-type ADP-ribosylating activity 
and has been shown to be as effective as LT for induction of immune responses (76). 
In addition, the adjuvant LT192, where LT has been altered by one amino acid 
substitution at the site of proteolytic cleavage, has reduced enterotoxicity (77). 
However, its adjuvanticity against coadministered antigens is retained, but 
-  1 5 -
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unfortunately it was shown to induce diarrhea in humans, at doses as low as 25 fig 
(78). 
CpG 
Unmethylated CpG dinucleotides with particular sequence context (CpG motifs), 
occur at high frequency in microbial DNA and stimulate the mammalian immune 
system (79). Mammalian immune system appears to have evolved Toll-like receptor 
9 (TLR-9) that distinguishes bacterial DNA from self DNA. Interactions between 
unmethylated CpG motifs in bacterial DNA and TLR9 in APC rapidly activate target 
cells through the Toll/IL-l-receptor signaling pathway to produce various 
proinflammatory and Thl-polarizing cytokines and chemokines, up-regulation of co-
stimulatory molecules on APC, and activation of B cells for proliferation, IL-6 
secretion and antibody production (79-81). The immunostimulatory features of 
bacterial DNA can be recapitulated by synthetic oligodeoxynucleotide (ODN) 
containing CpG motifs. The utility of CpG ODN as a Thl-tilting 
immunostimulator/adjuvant, either singly or in combination with various antigens, 
for induction of both systemic and mucosal immune responses in experimental 
animals has been reported (79, 82). In addition, CpG has been tested in humans 
against different disorders e.g. Hepatitis B (83, 84) cancer (85) and allergy (86), and 
has been shown to be safe and well-tolerated. 
Immunization studies against H. pylori 
There have been many immunization studies against H. pylori in fection in mice, 
using whole cell lysate, or single antigens together with an appropriate adjuvant (for 
examples, see Table 2). Both prophylactic and therapeutic immunization studies have 
been performed, although prophylactic studies dominate. Many of these studies have 
not conferred sterilizing immunity, but 1-2 log (i.e. 10-100 fold) reduction in bacterial 
load. Vaccine studies against H. pylori have been performed in humans, and although 
mucosal immune responses have been induced by both urease and inactivated whole 
H. pylori bacteria, they have not proven as successful as was hoped for (78, 87). 
Whether this has been due to use of inappropriate antigens or failure to mount 
sufficiently high H. pylori specific immune responses is not known. 
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Table 2. Immunization studies against Helicobacter in mice using protein antigen 
and adjuvants.  
Antigen Adjuvant Prophylactic/ Route of Ref 
Therapeutic administration 
Killed H. pylori CT Prophylactic Oral (88)* 
H. pylori lysate/ CT Therapeutic Oral (51, 89) 
inactivated whole-
cell H. pylori 
Urease LT Prophylactic Oral (90y 
Urease/CagA/ LTK63 Prophylactic Oral (74) 
H. pylori lysate 
Nap LTK63 Prophylactic Oral (44) 
VacA and CagA LTK63 Therapeutic Oral (40) 
H. pylori lysate Alum or Prophylactic Intraperitoneal (91) 
Freund's 
H. felis lysate CpG + CT Prophylactic Intranasal (92)a 
H. pylori lysate CpG Prophylactic Intranasal (93) 
H. pylori lysate CpG Prophylactic Subcutaneous (94) 
a Mice were challenged with H. felis 
Protective immune response against H. pylori. 
There is clear evidence that CD4+ T cells are required for protective immunity against 
H. pylori infection. Immunization of mice lacking MHCI, but not MHCII, are 
protected against H. pylori infection, suggesting that CD41, but not CD8+ T cells are 
required for effective immunity (95, 96). In addition, knockout studies have 
suggested that it is mainly CD4+ T cells of the Thl type that are responsible for the 
protective immunity because mice lacking IL-12 or IL-18 cannot mount a protective 
immune response against H. pylori (97, 98). 
However, the role of antibodies for immunity against H. pylori i s less 
clear. Czinn et al. showed that preincubation of bacteria with urease specific 
monoclonal antibodies decreased the bacterial infectivity (99). On the other hand, 
knockout studies have shown that mice lacking antibodies are equally well protected 
against challenge as wild-type mice (95, 100) and that antibodies actually may impair 
the gastritis seen, because mice lacking antibodies have more gastritis and also clear 
the infection quicker than wild-type mice (46). In addition, it has been demonstrated 
that the prevalence of H. pylori infection does not differ between IgA deficient and 
normal Swedish individuals (101). However, patients with IgA deficiency are at 
increased risk of developing gastrointestinal carcinomas (102, 103). Also, a recent 
study shows that gastric adenocarcinoma patients have decreased production of 
gastric IgA antibodies which may have an impact on the development of disease 
(Quiding-Järbrink et al., submitted for publication). However, it is not known 
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whether the low IgA production is a cause or effect of development of gastric 
malignancies. 
It is important to keep in mind that most conclusions regarding 
protective immune responses against H. pylori have been based on results from 
knock-out studies in mice, where compensatory mechanisms or alternative pathways 
to achieve immune-mediated protection might occur. It is therefore precautious to 
assume that CD8+ T cells or antibodies are irrelevant for protection; it could be that 
the antigens tested have not had the correct antigenic structure to induce the 
appropriate immune responses. Thus, it may be possible that different immune 
responses are important against different antigens, e.g. IgA may be effective against 
one virulence factor whereas cellular immune responses are important against 
another. Hence, until the mechanisms of immune protection have been further 
elucidated, it is better to have a vaccine that may induce both cellular and humoral 
immune responses. 
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AIMS OF THE STUDY 
The overall aims of this thesis were to study protection and related immune 
responses induced by therapeutic immunization against H. pylori in mice and also to 
identify candidate antigens for possible use in a therapeutic vaccine against H. pylori. 
The specific aims were: 
• To study the induction of innate immunity, i.e. chemokine responses, after 
oral administration of a putative mucosal adjuvant, CpG ODN, and to 
investigate its impact on an already established H. pylori infection. 
• To compare induction of protection by therapeutic immunization with 
different antigens and by different routes of administration. 
• To identify immune responses that are related to protection after vaccination 
against experimental H. pylori infection. 
• To establish methods for studies of mucosal T cell responses against H. pylori. 
• To evaluate the role of a candidate vaccine antigen, HpaA, for colonization of 
H. pylori in mice. 
• To identify candidate antigens for a therapeutic vaccine against H. pylori. 
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MATERIAL AND METHODS 
H. pylori strains and antigens 
H. pylori bacteria used for infection 
The mouse adapted strain H. pylori strain SSI (CagA+, VacA1, Le-V) (104) was used in 
all studies for infecting mice (89). Briefly, the bacteria were grown on Colombia-iso 
plates for 2-3 days before being transferred to liquid culture for over night culture. 
About 90% of the bacteria grown under liquid conditions have bacillary form and are 
motile which is essential for successful infection. The bacteria were resuspended in 
Brucella broth and adjusted to an ODœo of 1.5, and mice were orally infected with 
3xl08 colony forming units (CFU). 
H. •pylori antigens 
H. pylori strain Hel 305 (CagA+, VacA', Lex), a clinical isolate from a Swedish 
duodenal ulcer patient, was used for preparation of lysate as previously described 
(40). Plate grown bacteria were harvested in PBS and sonicated on ice before 
centrifugation and sterile filtration. The lysate was used for immunizing mice (II, IV) 
and for antigen specific T cell proliferation assays (II). 
Membrane preparations (MP) of H. pylori were prepared by sonication of bacteria of 
strain Hel 305 or SSI followed by differential centrifugation (105). The MP was used 
as antigen in ELISA for determination of antibody responses against H. pylori. 
Immunoblotting of MP and lysate of strain Hel 305 against some immunodominant 
antigens (Fig. 2) showed that they contain similar amounts of these antigens. 
HpaA, kindly provided by AstraZeneca (Boston, USA), was recombinantly produced 
and purified, as previously described (106). Urease was purified from H. pylori strain 
E32, which is a good producer of urease (25). H. pylori rCag antigen (Austral 
Biologicals, California, USA) was produced in genetically engineered E. coli and 
covers Glu 748 to Glu 1015 of the H. pylori CagA antigen. Nap and catalase were 
recombinantly produced in E. coli (107, 108) and were kindly provided by S. 
Nyström and C. Cederberg, respectively, AstraZeneca, Sweden. 
MP Ly 
Urease 
large Hsp 60 
subunit 
Urease 
sm all 
26kD 
Fig. 2. Membrane (MP) and lysate (Ly) preparations (15 (ig) of H. pylor i strain Hel 305 were 
blotted against H. pylori specific monoclonal antibodies (105,107). NAP was found in both 
preparations, but to a lesser degree in MP than in lysate (data not shown). 
Flagellin 
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H. pylori mouse model (Paper I-IV) 
The first mouse models of Helicobacter used H. felis as challenge strain (99) and H. felis 
has been extensively used in further studies (67,109-111). However, even though this 
Helicobacter model is well established, it has several disadvantages e.g. H. felis does 
not tightly adhere to gastric epithelial cells in vivo and it lacks CagA and VacA 
which are strongly associated with development of human disease (112). In addition, 
H. felis cannot be quantified by culture from the mouse stomach, making quantitative 
assessment of protection difficult. Last, but not least H. felis and H. pylori are different 
species. 
In this thesis, a well established mouse model of H. pylori has been used, in which 
female C57BL/6 mice are infected with the mouse adapted strain, Sydney Strain 1 
(SSI), resulting in stable colonization 1-8 weeks post inoculation (51). A recent study 
has demonstrated that the pattern of H. pylori proteins that are expressed in infected 
mice and become exposed to the mouse immune system appear to be similar to those 
in human H. pylori infections, suggesting that Helicobacter models may thus be valid 
to screen antigens for human vaccination (113). 
Therapeutic immunization of H. pylori infected mice (Paper II. IV) 
The focus of this thesis has been on therapeutic immunization, i.e. immunization of 
mice with an already established H. pylori infection. This was done by immunizing 
mice two weeks after infection, when the colonization is stable, with H. pylori antigen 
and adjuvant. In initial studies, four weekly doses with H. pylori lysate and CT were 
used for oral immunization, but subsequent studies (II) showed that two 
immunizations with a two week interval were actually more effective than four 
weekly doses. Therefore, in most cases the infected mice were orally immunized 
twice. For parenteral immunization, intraperitoneal (ip) immunization with H. pylori 
antigen and alum was given twice with a two week interval (Fig. 3). 
Fig. 3. Experimental set-up for therapeutic immunization studies against H. pylori 
H. pylori SS1 
Oral 
2 biweekly 
or 4 weekly doses of 
antigen + CT 
2 biweekly doses of, 
antigen + Alum 
Parenteral (ip) 
(II, IV). 
- 2 1  -
Experimental studies of H. pylori immunization 
Determination of bacterial colonization and immune responses induced by 
infection and therapeutic immunization (I-IV) 
For a summary of methods used in this thesis, see Table 3. 
Table 3. Methods used for determination of protection and immune responses. 
Determination of: Method Paper 
Bacterial load Quantitative culture I-IV 
Serum IgG+M antibodies ELISA3 II-IV 
Mucosal IgA antibodies in saponin extracts ELISA9 II, IV 
T cell responses in MLN CD4+ T cell proliferation assay II, IV 
Cytokine production Cytometric bead array, RT-PCRb II, IV 
Chemokines in saponin extracts ELISA" I 
Cell infiltration Hematoxylin and eosin staining I 
Characterization of SSI (Ah paA) DIGEC, FT-ICR MS'", RT-PCR1' III 
a ELISA; Enzyme Linked Immunosorbent Assay 
b RT-PCR; Reverse Transcriptase Polymerase Chain Reaction 
c DIGE; Differential In Gel Electrophoresis 
dFT-ICR MS; Fourier Transform-Ion Cyclotron Resonance Mass Spectrometry 
Determination of H. pylori in the stomachs of infected and immunized mice ( I-IV) 
Several different methods for detection of H. pylori bacteria in stomachs of m ice have 
been used, e.g. histology, urease test and culture of stomachs (32, 51, 114). While 
histology and culture are both quantitative, urease tests are not. In addition, the level 
of sensitivity for both histological and urease assays is about 105 bacteria per gram of 
tissue (52) and may therefore give false indications of sterilizing immunity after 
immunization. In contrast, culture of stomachs is a much more sensitive method with 
a detection limit of about 200 bacteria/stomach. Therefore, the bacterial load of H. 
pylori in the stomachs of infected and immunized mice was determined by 
quantitative culture of h omogenized stomach on Helicobacter-selective Skirrow blood 
agar plates. In cases of uncertainty, the H. pylori identity was confirmed by dot-blot 
staining using a monoclonal antibody against the H. pylori specific protein HpaA 
(26). Protection against H. pylori infection was defined as significant reduction in 
bacterial load compared to in control infected mice (p<0.05). 
Determination of antibody responses dl-IVI 
Serum IgG+IgM 
ELISA was used for determination of serum antibody titers against H. pylori. The 
coating antigen used was MP from strain SSI, but coating of th e plates with H. pylori 
lysate from Hel 305 gave comparable results (data not shown). We detected both 
serum immunoglobulin (Ig)G and IgM antibodies against H. pylori. 
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Mucosal IgA 
There are different methods to determine mucosal IgA antibodies, e.g. measurement 
of IgA in fecal pellets or in gut washings (115-117). However, the disadvantage of 
using these methods is that it is not known where in the gastrointestinal tract the IgA 
is being produced as it measures IgA in the luminal content. We have therefore used 
a reproducible and sensitive method for detection of mucosal IgA, e.g. saponin 
extraction of the mucosal tissues combined with ELISA (118). This method has the 
advantage of measuring both antibodies in specific compartments of the 
gastrointestinal tract, e.g. stomach and small intestine. Furthermore, both antibodies 
that have been secreted and antibodies that are in the tissue can be detected. For the 
extraction, stomach and small intestines were collected, washed in PBS, weighed and 
frozen in a PBS solution containing protease inhibitors, i.e. soy trypsin inhibitor and 
phenylmethylsulfonyl fluoride, as well as EDTA. Saponin was added to the solution 
to permeabilize the cell membranes. The samples were stored at 4°C overnight. The 
organs were spun down and the supernatant was analyzed for antibody content by 
ELISA. 
In the original study, mice were perfused in order to remove possible contamination 
of antibodies from the circulation. However we did not perfuse the mice since we 
could not detect any differences in H. pylori specific IgA titers in sera of immunized 
and infected mice indicating that it was mucosal IgA that was detected in the 
saponin extracts and not antibodies transudating from sera. In addition, this saponin 
extraction method was also used for detection of chemokines in stomach, small 
intestine and mesenteric lymph nodes (MLN) (paper I). 
Determination of mucosal T cell responses (Paper II. IV) 
To determine if an immunization regimen against H. pylori induces antigen specific T 
cell responses, spleen cells have been have chosen in many studies (91, 97, 119). 
However, spleen cells are not suitable for assessing mucosal T cell responses. Indeed, 
when comparing the proliferative response of spleen cells to that of MLN cells, it was 
clear that the MLN response better reflected the gastrointestinal responses induced 
by immunization because oral immunization induced a strong antigen-specific 
proliferation in cells from MLN but not from spleen (Fig. 4). We have therefore used 
MLN cells for determination of mucosal T cell responses after therapeutic oral 
immunization in our studies. 
Because CD4+ T cells have been implicated to play a critical role for protection 
against H. pylori (95-97), we sought to specifically evaluate the H. pylori-specific CD4+  
T cell response in immunized and infected mice. 
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Fig. 4. Antigen-specific proliferation of spleen and MLN cells in infected and immunized 
mice. Spleen (A) and MLN (B) cell proliferation using cells from control infected and therapeutically 
immunized mice stimulated with H. pylori antigen. Inf; control infected mice (n=8), oral; infected and 
orally immunized mice (n=8), ip; infected and ip immunized mice (n=6), naïve; neither infected nor 
immunized mice (n=4). Stimulation index (SI) was determined by calculating the ratio between the 
proliferation of cells stimulated with antigen and with medium alone. **, pO.Ol compared to control 
infected mice. 
Antigen- specific CD4+ T cell prol iferation (Paper II, IV) 
To determine the antigen-specific CD4+ T cell responses, we first started by simply 
coculturing CD4+ T cells purified from MLN with H. pylori lysate and antigen 
presenting cells. However, the antigen seemed to be toxic to the isolated T cells, 
because these cells died by the antigen stimulation. We therefore established a 
method to circumvent the toxicity. In this method, either B cells or DC were used as 
APC and were pulsed with H. pylori-antigen over night, and any unprocessed 
antigen was washed off before culturing the cells together with purified CD4+ T cells 
(Fig. 5). Supernatants were taken after 48 and 96 h for determination of cytokines by 
cytometric bead array (CBA). The proliferation of cells was determined after four 
days of culture and measured by thymidine incorporation. 
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Fig. 5. Schematic picture of the antigen-specific CD4+ T cell proliferation assay. 
Proteomics (Paper III} 
In paper III we used an SSI (AhpaA) mutant to study the physiological role of HpaA 
for H. pylori colonization in mice. To ascertain that disruption of the hpaA gene had 
not introduced any second site mutations or caused any polar effects on its 
downstream genes, the protein expression patterns of the mutant and the wild-type 
strains were compared by a proteomic approach since it is a convenient method of 
monitoring changes in protein expression without prior knowledge of what those 
changes might be. 
Two-dimensional gel electrophoresis (2D-GE), in which proteins are separated both 
dependent on their molecular weights and isoelectric points, is a powerful method 
for separation of complex protein mixtures. However, one disadvantage with this 
method is the problem of reproducibility between different gels. 
Thus, differential in gel electrophoresis (DIGE) was used to compare the overall 
protein expression of the wild-type and mutant strains. In this method, two sets of 
protein mixtures are run in the same gel, which minimizes the problems with 
reproducibility. By labelling the different samples with fluorescent dyes, the protein 
profile of each sample can easily be imaged by fluorescent excitation of the different 
dyes. In addition, an internal standard is co-run together with the samples which 
enables a comparison between different gels. In this study, lysates of the wild-type 
and mutant strain were compared using DIGE analysis. By the use of a computer 
program, the protein expression of the wild-type and mutant strains could be 
determined. Protein spots that were significantly altered (p<0.05) were selected for 
identification by mass spectrometry (MS). 
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Hydrophobic proteins, e.g. membrane proteins, are known to be discriminated in 2D 
gels. We therefore compared the outer membrane protein (OMPs) profiles of the 
wild-type and mutant strains by subcellular fractionation of OMPs in combination 
with 1D-GE followed by high sensitivity nano-LC and MS analysis. 
Statistics 
In the first two papers Mann-Whitney was used for statistical analysis. However, we 
used Student's t-test for the last two papers because this test could be more 
appropriate for our comparisons between groups. The analysis was made using 
Prism software system (GraphPad Software Inc, San Diego, California). P<0.05 was 
considered significant. *; p<0.05, **; pcO.Ol, ***; pO.OOl, ns; not significant. 
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RESULTS AND COMMENTS 
Induction of CXC and CC chemokines in the gastric mucosa and 
protection against experimental H. pylori infection after oral 
administration of CpG ODN (Paper I) 
The impact of oral administration of the Thl tilted immunostimulator (79, 82) CpG 
ODN on induction of immune responses against experimental H. pylori infection was 
studied in mice. This included studies of the induction of innate immune responses, 
e.g. chemokine production, in the stomach, small intestine, MLN and serum at 
various time points after oral administration of CpG ODN to naïve mice. In addition, 
we also sought to evaluate the impact of C pG ODN administration on an established 
H. pylori infection. 
Chemokine production after oral CpG ODN administration 
The chemokines that were studied are known to be important for recruitment of 
various immune cells (Table 4). Furthermore, RANTES, together with MIP-la and 
MIP-lp are associated with a Thl type of immunity, and IP-10 preferentially recruits 
T cells. 
Table 4. Chemokines studied in Paper I. 
Chemokine Produced by Recruitment of 
IP-10 (CXC) Monocytes, lymphocytes, 
endothelial cells 
T cells (120) 
RANTES (CC) Monocytes, macrophages, 
T cells, epithelial cells, 
eosinophils 
Monocytes, T cells, NK 
cells, DC (121) 
MIP-la (CC) Monocytes, macrophages, 
lymphocytes, neutrophils, 
eosinophils 
Monocytes, T cells, 
neutrophils, NK-cells, 
DC (120) 
MIP-ip (CC) Macrophages, T cells, B cells, 
neutrophils, 
Monocytes, T cells, 
basophils (120) 
We found that administration of a single dose of m urine specific CpG ODN to naïve 
mice resulted in a biphasic secretion of all the chemokines studied, as shown by 
analysis of saponin extracts of stomach and small intestine. The increased production 
of these chemokines could neither be detected in MLN, nor in the blood after oral 
administration, suggesting that the immune responses induced were specific to the 
gastrointestinal tract and not systemic. In addition, increased production of IP-10 and 
RANTES could be detected both in the stomach and small intestine, whereas MIP-la 
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could only be detected in the stomach and MIP-lß in the small intestine. A few hours 
post CpG ODN administration, the first peak of chemokine production was seen in 
the small intestine and stomach; peak responses of RANTES, MlP-la and MIP-lß 
were seen before that of IP-10 (Fig. 6 and paper I). This may suggest that the 
increased production of the CC chemokines (RANTES, MlP-la and MIP-lß) is a 
prerequisite for induction of an increased expression of IP-10; i.e. CC chemokines 
recruit cells that produce IP-10 or stimulates cells for such production. In addition, 
second peaks were also observed that lasted for up to, or more than one week (last 
time point examined) post CpG ODN administration. This suggests that the source of 
the early chemokine response (hours after CpG ODN administration) is tissue 
resident immune cells and the second peak of chemokine response (days after CpG 
ODN administration) is from cells specifically recruited to the tissue. Indeed, staining 
for macrophages confirmed the presence of these cells in the gastric mucosa of naïve 
and H. pylori infected mice (data not shown). 
048 24 72 96 168 0 8 24 72 96 
Hours post CpG ODN treatment Hours post CpG ODN treatment 
048 24 48 72 96 168 
Hours post CpG ODN treatment 
1 C RANTES 
MIP-1ß 
Hours post CpG ODN treatment 
D IP-10 
2000 
MIP-1a 
Fig. 6. Chemokine production at various time points in the gastrointestinal tract after oral 
CpG ODN administration. 
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Based on these results, the following model for induction of chemokine responses 
after CpG ODN administration is suggested (Fig. 7): 
(1) CpG ODN binds to TLR-9 in epithelial cells and tissue resident macrophages or 
DC in the gastrointestinal tract. (2) Epithelial cells produce RANTES, which activates 
monocytes and NK cells present in the tissue and recruits new cells to the gastric 
mucosa. (3) Alternatively, CpG ODN stimulates DC or macrophages which secrete 
MIP-la and/or MIP-lß, leading to recruitment of NK cells, monocytes and T cells. (4) 
Activated NK cells and T cells present in the tissue are a source of IFN-y that can in 
turn (5) stimulate monocytes to produce IP-10. In addition, RANTES and IP-10 are 
known to recruit T cells and other cells to the Gl-tract, leading to the amplification of 
the immune response, which could explain the second peak of chemokine secretion 
(6). 
CpG 
Epithelial cells 
DC/M0 
RANTES 
MIP-1 oc/ß IP-10 NK )( Mono Tc 
NK )(MonoXTc 
iMono) 
IFN-y-
Fig. 7. A model for the induction of chemokine responses in the 
stomach after oral CpG ODN administration. 
Mono; monocytes, M0; macrophages, Tc; T cells 
Bacterial colonization of H. pylori in the stomach 
Because of the induction of innate immune responses after administration of CpG 
ODN to naïve mice, we next wanted to investigate if oral delivery of CpG ODN 
could induce immune responses that could reduce the bacterial load in mice with 
established H. pylori infection. To this end, H. pylori infected mice were immunized 
twice with CpG ODN and the bacterial load in infected and immunized mice were 
determined three days after each dose. Significant reduction in bacterial load could 
be detected after the second dose, but not after the first dose (I). 
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H. pylori infection in mice results in chronic gastritis which develops six to eight 
months post inoculation (104). This is similar to the findings in human chronic 
gastritis which is also Thl driven, and mononuclear cells (e.g. B and T cells) as well 
as polymorphonuclear cells (e.g. granulocytes and macrophages) are found at the 
inflammatory site (122, 123). Importantly, immunization of mice quickly results in 
post-immunization gastritis, which resolves over time when the colonization is 
reduced (51, 97, 124). Indeed, the reduction in bacterial load after CpG ODN 
administration was reflected by an increase in infiltrating cells to the site of infection 
as well as an increased RANTES production locally in the stomach compared to 
control infected mice (I). 
This study was the first to demonstrate that CpG ODN could induce mucosal 
immune responses and reduce the H. pylori load in infected mice. There have been 
subsequent studies showing the efficacy of CpG ODN as a mucosal adjuvant for an 
H. pylori vaccine in mice (92,93). 
Immunization with H. pylori lysate and CpG ODN or CTB-CpG 
In an attempt to refine and improve the immunization regimen to induce further 
reduction of H. pylori colonization in infected mice, CpG ODN was conjugated to 
CTB and given together with H. pylori antigen intranasally (Nystrom J et al, 
unpublished). The rationale for using CTB-CpG as an adjuvant in this study was to 
combine the immunostimulatory effects of CpG ODN with the ability of CTB to bind 
to cells, especially APCs, and to shuttle CpG ODN more effectively into TLR-9 in 
sub-cellular compartments. Indeed, previous studies in our department have 
elegantly shown that the immunostimulatory effect of CpG ODN could be readily 
enhanced by conjugation to CTB (125) and that such conjugate confers protection 
against a subsequent challenge with a lethal dose of herpes simplex virus type 2 
(Adamsson J, unpublished data). We found that intranasal immunization of mice 
with H. pylori lysate in combination with CpG ODN or CTB-CpG induced significant 
protection against a subsequent H. pylori challenge, but conjugation of CpG to CTB 
did not improve the adjuvanticity of CpG against H. pylori infection (Fig. 8). 
However, intranasal immunization with CpG ODN and lysate required less adjuvant 
than oral administration (I) (5 and 30 [ig, respectively) and also lasted longer than 
oral CpG ODN administration. 
- 3 0 -
Results and Comments 
Infected CTB-CpG 
Fig. 8. Protection against challenge with H. pylori by intranasal 
immunization with H. pylori lysate together with CTB, CpG or CTB-
CpG. 
Groups of mice ( n = 15 to 20) were immunized intranasally with H. pylori 
lysate together with CTB, CpG ODN or CTB-CpG 3 times, 10 days apart. 
Two weeks after the last immunization, the mice were challenged 
intragastrically with H. pylori. The mice were sacrificed two weeks after 
challenge, and the bacterial loads were quantified by culture, ns; not 
significant, **; p<0,01 compared to control infected mice. Results shown are 
pooled from two independent experiments. 
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Induction of protection by different routes of therapeutic 
immunization and relation between protection and mucosal immune 
responses against H. pylori (Paper II). 
For the design of an effective candidate vaccine against H. pylori infection, immune 
responses that may predict the outcome of an immunization regimen (sterilizing 
protection or reduction in bacterial load in the stomach) should be identified, 
particularly after therapeutic immunization. In this study we compared the bacterial 
colonization in the stomach of H. pylori infected mice after oral and systemic 
therapeutic immunization, respectively, using immunization strategies (H. pylori 
lysate + adjuvant, Fig. 3) that have previously been shown to be effective for 
prophylactic immunization (88, 91). We also evaluated whether systemic and/or 
mucosal immune responses may be used as markers to predict protection against an 
ongoing H. pylori infection. 
Bacterial colonization of H. pylori in the stomach after therapeutic immunization 
We found that oral immunization of infected mice with H. pylori lysate and CT, given 
four times at weekly intervals, induced a significant reduction in bacterial load 
compared to in control infected mice (p<0.01) (Table 5 & Paper II). In contrast to the 
oral immunization, two ip immunizations given with a two week interval failed to 
induce protection against H. pylori. To exclude the possibility that the different 
outcomes of the two immunization regimens were due to the different number of 
immunizations, we also studied colonization in mice orally immunized twice with a 
two week interval. Interestingly, two oral immunizations every other week were 
even more effective than four weekly doses in reducing the bacterial colonization. 
These results are in agreement with a previous study using prophylactic 
immunization, and may be due to the boosting immunization being more effective if 
the stimulation induced by the priming dose has faded away (52). However, there 
were no significant differences between immune responses induced by two or four 
oral immunizations (Table 5). 
Systemic and local antibody responses 
Both oral and ip immunization resulted in increased serum IgG+IgM titers compared 
to titers in control infected mice (Table 5 & Paper II). Further analysis of the specific 
antibodies of IgG subclasses IgGl (Th2) and IgG2c (Thl) showed that both 
immunizations induced significantly higher titers of IgGl than of IgG2c in serum 
(pO.Ol) (Paper II). Thus, both immunizations induced systemic Th2 responses as 
judged by IgG subclasses. In contrast to the serum antibody responses, only oral 
immunization resulted in significantly increased IgA antibodies against H. pylori in 
the stomach (Table 5 & Paper II). Hence, in spite of the strong serum antibody 
response, therapeutic ip immunization did not induce local IgA responses against H. 
pylori. However, although H. pylori-specific IgA antibodies can be regarded as an 
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indicator that the immune response has reached the mucosal surface, we could not 
demonstrate a direct correlation between specific IgA levels and the bacterial load in 
individual mice. Other studies have shown increased levels of H. pylori-specific 
mucosal IgA in fecal extracts after oral immunization with H. pylori antigen and a 
strong mucosal adjuvant (116, 117, 126). The present study supports and extends 
these findings, since the saponin-extraction method allows determination of where in 
the gastrointestinal tract the antibodies are produced and secreted. Thus, we could 
show that oral immunization gives rise to induction of H. pylori-specific IgA 
antibodies in the stomach. 
Cellular immune responses 
To be able to study the mucosal T cell response in infected and immunized mice, we 
first had to develop a new method for determination of H. pylori-specific CD4+ T cell 
responses (II). Ideally we should evaluate the CD4+ T cell responses directly in the 
stomach or in the gastric lymph nodes but this precludes assessment of protection 
and T cell response in the same mice. One alternative possibility, which has been 
used by other groups after prophylactic immunization (91, 97, 119), is to investigate 
the cellular immune responses in the spleen against H. pylori antigens. However, we 
could show that the splenic cellular immune response did not reflect mucosal 
immunity, since the oral therapeutic immunization which induced protection against 
H. pylori, was not able to induce any antigen-specific proliferation of splenic cells 
(Fig. 4). Instead, we evaluated if MLN could be used as a predictor of gastric 
immunity and a source for mucosal CD4+ T cells. Antigen stimulation of the total 
MLN cell population seemed to reflect mucosal immunity because orally immunized 
mice (which were protected) showed higher proliferation than control infected and 
ip immunized mice (which were not protected). Since CD4+ T cell responses have 
been shown to be important for protection against H. pylori (91, 95-97), we further 
wanted to investigate the antigen-specific response of CD4+ T cells from MLN. 
However, culturing purified CD4+ T cells with B cells or DC as APC together with H. 
pylori lysate resulted in death of the stimulated cells. This may be due to the VacA 
which is present in the lysate and has the ability to block T cell activation (42). To 
circumvent this toxicity, the APC were first pulsed with antigen over night, 
thereafter any unprocessed antigens were washed off and the APC were cultured 
with CD4+ T cells (Fig. 5). 
Similarly to the IgA response, only the oral immunization induced substantially 
increased antigen-specific CD4+ T cell responses, whereas such increase was not 
detected after ip immunization. This suggests that protection against H. pylori was 
related to effective mucosal CD4+ T cell responses (Table 5 & Paper II). In addition, 
analysis of the cytokine production showed that cytokines were mainly detected in 
cell cultures from orally immunized mice and the production was related to the 
degree of proliferation of the cells. The cytokine profile of the CD4+ T cell responses 
was of the Thl type (II), because there was a substantially increased production of IL-
2, TNF-a and IFN-y whereas no IL-4 or IL-5 were found in the supernatants. The low 
- 3 3  -
Experimental studies of H. pylori immunization 
Th2 response seen could be due to that IL-4 or IL-5 were rapidly utilized by cells, 
making them undetectable in the supernatants. We however ruled out the 
production of Th2 cytokines by the T cells at the mRNA level in the cells isolated 
from the different groups of mice and found no expression for the IL-4 gene. Thus, 
protection against an ongoing H. pylori infection was reflected by increased mucosal 
CD4+ T cell responses with a Thl profile. 
Table 5. Bacterial load and immune responses after oral and ip immunization. 
Oral immunization IP Infection 
2 doses 4 doses immunization controls 
Fold decreases in CFUa 25*** |Q *** 2.5 
CD4+ T cell proliferation11 19 ± 11"' 2.2 ±1.2 3.3 ±1.8 
Mucosal IgA'1 130 ± 47 ** 171 ± 53 ** 5 ± 2 5 ± 1 
Serum IgG+Md 5416±3367*** 13013±4484*** 64216 ±9234*** 711 ±423 
" Fold decrease in colonization in the stomach was calculated as the ratio between geometric 
means (GM) of CFU in immunized and control infected mice. 
b Data shown as stimulation index (SI). SI was determined by calculating the ratio between 
the proliferation of CD4+ T cells stimulated with antigen or medium alone. 
cData shown is combined from two and four oral immunizations. 
d Titers expressed as GM ± SD 
**; pO.Ol, ***, pO.OOl compared to control infected mice. 
Because administration of CpG ODN induced high chemokine production in the 
stomach and small intestine (Paper I), we wanted to investigate whether oral 
immunization with H. pylori l ysate and CT could induce such production as well. 
Indeed, orally immunized mice had an increased production of RANTES and IP-10 
in their stomachs compared to control infected mice (data not shown). In contrast to 
CpG ODN administration, immunization with CT alone failed to induce such 
production. However, in this study, the chemokine production was evaluated two 
weeks after the last booster at variance with paper I where the chemokine response 
was determined up to one week post CpG administration. Furthermore, we have not 
studied post-immunization gastritis after immunization in this study because a 
previous report by our group has shown that oral therapeutic immunization with 
lysate and CT induces post-immunization gastritis (89) and others have shown that 
therapeutic ip immunization with lysate and alum did not induce significant gastritis 
(127). 
In summary, in this study we have shown that the oral, but not the ip, immunization 
protocol used was capable of inducing protection against H. pylori. The protection 
was related to increased H. pylori-specific responses; both mucosal IgA levels in the 
stomach as well as Thl biased CD4+T cell responses. 
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HpaA as a candidate antigen for a therapeutic vaccine against H. pylori 
(Paper III & IV) 
The optimal candidate antigen in a bacterial vaccine should be surface exposed, 
species-specific, conserved (i.e. present in all strains) and immunogenic (i.e. capable 
of stimulating the immune system). HpaA fulfils all these criteria; it is present on the 
bacterial surface (22, 23) and is expressed by all H. pylori isolates tested (26). In 
addition, HpaA is immunogenic in humans (25, 128). Furthermore, HpaA does not 
have any homologies or similarities with any other known proteins (27, 28). Taken 
together, these data suggested to us that HpaA may be important for H. pylori 
virulence and a possible candidate antigen for use in an H. pylori vaccine. 
Therefore, to investigate the importance of HpaA for H. pylori infection in mice, we 
introduced a previously described mutation (19) of hpaA into the mouse adapted 
strain SSI by natural transformation. The insert in the isogenic mutant was 
confirmed by PCR and immunoblotting. However, in order to verify that the 
mutation had not caused any damage on downstream genes, i.e. ompl8 (HP0796) and 
tig (HP0795), that are being cotranscribed with HpaA (Fig. 9) (22) or second site 
mutations e.g. changes in other parts of t he genome, we used RT-PCR and proteomic 
methods to characterize the mutant (III). The proteomic approach was chosen 
because it enables monitoring of changes in protein expression without prior 
knowledge of what those changes might be, as in the case of second site mutations. 
In addition, this approach has been used in other studies for characterization of 
bacterial mutants (129,130). 
+ + + 
SSI 
hpaA ompl8 
HP0795 
+ 
HP0797 HP0796 
+ 
SSI (AhpaA) 
/ Kariamycine \ 
resistance cassette 
Fig. 9. Localization of hpaA and its downstream genes ompl8 and tig. 
hpaA w as functional in the wild-type (SSI) but not in its isogenic mutant. 
Ompl8 and Tig could be detected in similar amounts in the wild-type and 
mutant strains by RT-PCR and DIGE-analysis, respectively. 
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Comparison of the major proteome components of SSI and SSI (AhpaA) 
To examine the effects on the overall protein profile of SSI and its isogenic mutant, 
we performed DIGE analysis on whole cell lysates of the two strains (III). Over 800 
protein spots could be detected, and of these 13 spots corresponding to 11 proteins 
showed small changes in expression levels in the mutant compared to the wild-type 
strain (p<0.05). 
Two of the down-regulated proteins, the gamma-glutamyl transferase (GGT) and the 
non-heme ferritin protein (Pfr) have previously been pointed out as potential 
virulence factors important for H. pylori colonization. A recent study showed that 
GGT provides some advantage in colonization, but it was not essential for 
establishment of H. pylori infection (131). Pfr, which is a major iron storage protein of 
H. pylori (132-134) was previously shown to have an essential role for the iron 
resistance of H. pylori (133). In addition, a pfr mutant was unable to colonize gerbils 
(135). Moreover, while the mutant could grow as well as the wild-type under 
standard conditions, its growth was significantly decreased when grown in a 
medium with acidic pH supplemented with ferrous iron. The HpaA mutant showed 
no such changes in growth rate under the same conditions as described above (data 
not shown). Furthermore, it has previously been shown that minor changes normally 
occur within a bacterial strain (136, Carlsohn E; unpublished data). Taken together, 
these minor variations in protein expression between the wild-type and its isogenic 
mutant should not affect the colonization ability of the HpaA mutant. 
The most important finding of the DIGE analysis was that the Tig protein could be 
detected in similar amounts in both strains (Paper III). Furthermore, all the OMPs 
that were detected in the wild-type strain, apart from HpaA, were also expressed in 
the mutant strain (III). The Ompl8 protein could not be detected in either strain but 
to the best of our knowledge, it has never been detected which may indicate that it is 
not being translated. Nevertheless, we could detect Ompl8 mRNA transcripts both 
in SSI and its isogenic mutant by RT-PCR, suggesting that the mutation had not 
caused any damage on the ompl8 gene (data not shown). In vitro of the wild-type 
and mutant SSI strains showed that both strains grew equally well in liquid shaking 
culture, as measured by absorbance at ODéoo and viability (Table 6 and Paper III). 
Detection of bacteria in H. pylori infected mice 
Because both proteomic and in vitro culture studies of SSI and its isogenic mutant 
SSI (AhpaA) showed high similarity between the two strains we next moved on to 
evaluate the role of HpaA for H. pylori colonization. This was done by infecting mice 
with either strain and determine the colonization at various time points post-
inoculation by quantitative culture and H. pylori-specific PCR. While infection of 
mice with SSI resulted in heavily colonized mice at all time points examined (3 days, 
3 and 8 weeks), inoculation with the mutant strain failed to establish H. pylori 
colonization at any time point (Table 6). Furthermore, complementation experiments 
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to show that reintroduction of HpaA expression to the mutant restores its ability to 
colonize mice have been undertaken. 
We also analysed the serum antibody response in the infected mice against both H. 
•pylori M P and HpaA by ELISA. As expected, mice infected with the wild-type, but 
not the mutant strain, showed high IgG+IgM antibody levels against both antigen 
preparations (Table 6). Detection of antibodies against HpaA in mice infected with 
SSI supports the immunogenicity of this antigen. 
Thus, we could show that HpaA is an H. pylori-specific colonization factor in mice, 
establishing for the first time a physiological role of HpaA in vivo. 
Table 6. Properties of the wild-type and HpaA-negative mutant strain  
SSI SSI (AhpaA) 
Growth in vitro +++ +++ 
Viability in vitro +++ +++ 
Number of CFTJ in infected mice 6.5xl06 Not detectable (<200) 
Detection of UreA in infected stomachs by PCR +++ Not detectable 
Serum IgG+M against MPa 3550 ± 389** 269 ± 781,5 
Serum IgG+M against HpaAa 559 ± 262** 88 ± 53"15 
a Titers expressed as GM ± SD (n=5). 
ns; not significant **; pO.Ol, compared to uninfected mice. 
Identification of protective antigens 
We next wanted to identify candidate antigens for a therapeutic vaccine against H. 
pylori. Because we could show in paper II that oral immunization with H. pylori lysate 
could induce protection against H. pylori and that it was related to antigen-specific 
mucosal T cell responses, we sought to identify antigens in the lysate that may 
contribute to the protective immune responses. To this end, MLN cells from control 
infected as well as lysate immunized mice were stimulated with antigens that are 
known virulence factors and present in the lysate i.e. urease, Nap, Cag, catalase, and 
HpaA. While urease, Nap and Cag induced significantly stronger proliferative 
responses in immunized mice than in control infected mice (IV), catalase and HpaA 
did not induce any such increased response. The proliferation of urease and Nap-
stimulated cells correlated to the bacterial load seen in individual mice (pcO.Ol and 
p<0.05 respectively, data not shown). 
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Protection against H. pylori infection after immunization with HpaA 
The fact that immunization with lysate did not induce any HpaA-specific cellular 
response was somewhat surprising; especially in the light of HpaA being a 
colonization factor and that immunity against HpaA may therefore be important for 
protection against H. pylori. However, the low immune response could be due to 
HpaA being present in relatively low amounts in the lysate. To evaluate if immune 
responses against HpaA may protect against H. pylori, mice were immunized orally 
with HpaA and CT. Indeed, HpaA was shown to be a protective antigen against H. 
pylori in mice and the protection was even more effective when mice were 
immunized orally with HpaA together with urease (Table 7 and paper IV). In fact, in 
some mice sterilizing immunity had been induced (i.e. no culturable bacteria were 
detected) after oral immunization with HpaA alone or together with urease. 
However, ip immunization with HpaA and Alum did not induce any significant 
reduction in bacterial load. 
When comparing the reduction in bacterial load after immunization with the 
different antigen preparations used in this thesis, immunization with HpaA in 
combination with urease induced the greatest reduction in bacterial load (Table 7). 
Thus, based on these results it may be suggested that a therapeutic vaccine against H. 
pylori should optimally contain a cocktail of a few antigens, including HpaA and 
urease. 
Table 7. Comparison of reduction of bacterial load after diffe rent immunization 
regimens (Paper II, IV). 
Vaccine Route GM bacterial load 
(logio + SD) 
Fold decrease3 
Control infected mice 6.3 ± 0.23 
Lysate + CT Oral 4.9 ± 0.6 (2 doses) 25*** 
5.3 ± 0.8 (4 doses) 10*** 
Lysate + Alum IP 5.9 ±0.8 2.5 
HpaA + CT Oral 4.1 ±1.5 160*** 
HpaA + urease + CT Oral 3.5 ±1.2 630*** 
HpaA + Alum IP 5.7 ±0.2 4 
a Compared to control infected mice. ***, p<0.001. 
Immune responses against HpaA after therapeutic immunization 
Similarly to the immune responses induced by H. pylori lysate immunization, 
protected mice exhibited increased antigen-specific CD4+ T cell proliferation of the 
Thl type and also increased titers in HpaA specific mucosal IgA antibodies 
compared to control infected mice (IV). Because sterilizing immunity against H. 
pylori had been induced in some mice it would be of interest to look into individual 
immune responses, particularly in these mice. However, there was no relation 
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between mucosal IgA responses and protection in individual mice, and the CD4+ T 
cell analysis was performed on cells that were pooled from different mice in order to 
get enough cells, but it seems plausible that the difference in protection could be 
explained by the degree of T cell responses in individual mice. 
The antibody response against HpaA was relatively low in control infected mice 
suggesting that HpaA is a weak immunogen during infection. The same holds true in 
humans, where H. pylori infected individuals have low mucosal antibody responses 
against HpaA, e.g. low levels of HpaA-specific SIgA and antibody secreting cells 
were detected in the stomachs of asymptomatic individuals and duodenal ulcer 
patients (25, 137). Our studies in mice show that it is possible to boost a strong 
immune response against HpaA in mice by therapeutic immunization (IV). However, 
our preliminary data suggest that priming, e.g. by infecting mice may be a 
prerequisite for mounting high immune responses because HpaA immunization of 
mice, in the absence of infection, failed to induce proliferative responses in MLN 
(data not shown). 
In summary, these studies clearly show that HpaA is a H. pylori-specific colonization 
factor and a promising candidate antigen for a therapeutic vaccine against H. pylori. 
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GENERAL DISCUSSION 
H. pylori infects more than half of the world's population, making it one of the most 
common gastrointestinal infections world-wide. The current antibiotics-based 
treatment against H. pylori is associated with several drawbacks e.g. high cost, low 
compliance and most importantly the rapid increase of antibiotics resistance. A 
vaccine against H. pylori would therefore be a cost-effective and attractive alternative 
or complement to the current treatment. 
A vaccine can be given either prophylactically; i.e. before an individual becomes 
infected, or therapeutically; i.e. against an already established infection. A 
therapeutic vaccine would also have the advantage over the antibiotics-based 
therapy in that it provides appropriate immunological memory to avoid re-infections 
(40, 51, 89). Experimental vaccine studies in mice have shown that both prophylactic 
and therapeutic immunizations have conferred protection against H. pylori (40, 88-
90). Most immunization studies against H. pylori infection in mice have used 
prophylactic regimens. However, the focus of this thesis has been on therapeutic 
immunization. One reason for this is earlier studies in our group showing that gastric 
immune responses could not be induced in uninfected, but only in H. pylori infected 
individuals, when given a model vaccine (138). We have also focused on using a 
mucosal immunization strategy against H. pylori to induce immunity at the site of 
infection. In addition, other advantages of mucosal immunization includes the ease 
of administration and the reduced, or minimal, risk of e.g. HIV and Hepatitis B virus 
transmission that can occur with injectable vaccines. 
In this thesis a well established mouse model of H, pylori infection (51, 52, 104) has 
been used to study the immune responses and protection induced by therapeutic 
immunization. However, it is important to keep in mind that results from mouse 
studies may not be translated directly into humans. This is especially true for studies 
using knock-out mice in order to elucidate components of the immune system that 
may be important for protection against H. pylori. On the other hand, recent reports 
support the validity of using wild-type mouse models of H. pylori for vaccination 
studies. First, H. pylori proteins that are expressedin infected mice and are exposed to 
the mouse immune system appear to be similar to those in human H. pylori 
infections, suggesting that H. pylori models may be suitable for screening antigens 
for human vaccination (113). In addition, a human vaccination and challenge model 
has recently been established (139, 140). In this model, human volunteers were 
vaccinated with live typhoid vaccine (Ty21a) expressing urease before challenge with 
an antibiotics-susceptible H. pylori strain lacking CagPAI and other antigens 
associated with severe disease outcome. Although only a few of the vaccinees were 
cleared of their infection, analysis of the immune response induced in these 
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individuals revealed that, similar to protective immune responses in mice (II, 95-97, 
141), CD4+ T cell response of the Thl type was associated with protection. These 
findings support that the mouse model may be used for identification of protective 
immune mechanisms and candidate antigens. 
Many immunization studies against H. pylori infection in mice have used powerful 
mucosal adjuvants (51, 88-90), e.g. CT and LT, which cannot be used in humans 
because of their toxicity (65). Therefore there is a great need to develop a safe and 
non-toxic adjuvant for mucosal use. 
Bacterial DNA has been shown to stimulate the vertebrate innate immune system, 
and it is CpG dinucleotides with appropriate flanking regions that are responsible for 
this activation through binding to TLR-9 (80, 81). Because of i ts immunostimulatory 
effect, CpG ODN has been evaluated as an adjuvant both in mice and in humans (84, 
85, 142). When we started this study, systemic administration of C pG ODN had been 
shown to confer protection against different infections in mice such as Leishmania 
major (142) and Listeria monocytogenes (143). In addition, studies in our laboratory had 
demonstrated that vaginal-mucosal administration of CpG ODN induced protection 
against genital herpes infection and disease (144). However, the adjuvant effect of 
CpG ODN on the gastric mucosa had not been studied. We therefore sought to 
investigate whether oral CpG ODN administration could influence the innate 
immune responses in the gastrointestinal mucosa and also to evaluate the impact of 
CpG ODN on an established H. pylori infection (I). CpG ODN is an interesting 
adjuvant against H. pylori infection as it induces Thl polarized responses and 
recently several studies (97, 145) have shown that Thl and not Th2 responses (146) 
are necessary for protection against H. pylori. Indeed, we could show that a single 
dose of CpG ODN could induce a rapid and strong induction of the chemokines 
RANTES, MlP-la, MIP-lß and IP-10 in the gastrointestinal mucosa (I). However, no 
increase of these chemokines in the mesenteric lymph nodes or sera of these mice 
could be detected, suggesting that CpG ODN has a local effect. In addition, 
administration of CpG ODN to H. pylori infected mice resulted in a significant 
decrease in the bacterial load, which was associated with infiltration of immune cells 
to the gastric mucosa and an increased RANTES production. 
There have been concerns that CpG ODN could enhance the immunogenicity of s elf-
antigens, which could lead to development of autoimmune diseases. However, 
repeated ip immunizations of high doses of CpG ODN did not cause any adverse 
effects in mice (147). In addition, clinical studies using CpG ODN as part of a vaccine 
strategy against hepatitis B or cancer have reported that CpG ODN is well tolerated 
by the patients (84, 85). Thus, CpG ODN seems to be a safe adjuvant that can be 
administered mucosally. However, the optimal dose of CpG ODN required for 
administration to the mucosal site in order to achieve protection against H. pylori 
remains to be evaluated. 
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We next wanted to compare protection induced by different routes of immunization 
and also to identify immune responses that could reflect protection induced by 
therapeutic immunization, i.e. find markers for protective immunity. To this end, 
mice were orally or ip immunized with H. pylori lysate and adjuvants using protocols 
that have conferred protection when used prophylactically (88, 91). In contrast to the 
prophylactic immunization, only the oral, but not ip immunization with II. pylori 
lysate and adjuvant was able to induce protection against H. pylori when given 
therapeutically (II). Furthermore, we could clearly demonstrate that oral, but not ip, 
therapeutic immunization resulted in significantly increased antigen-specific CD4+ T 
cell responses in MLN (II). Analysis of the cytokine production showed that 
cytokines were mainly found in T cell cultures from orally immunized mice, and that 
they had a Thl profile; i.e. they produced increased levels of IFN-y and TNF-a but 
no IL-4 or IL-5. This is in line with previous studies showing the importance of Thl 
responses for protection against H. pylori (97, 145). Our study is the first to make a 
comprehensive comparison on the effect of two different immunization routes on the 
mucosal T cell responses and protection against H. pylori infection in 
immunocompetent mice. 
The role of antibodies, in particular mucosal IgA, for protection against H. pylori is 
less clear than the role of T cells. Knock-out studies have shown that B cells and 
antibodies are dispensable for protection against H. pylori (95, 100). However, 
preincubation of H. felis with monoclonal IgA antibodies against urease protected 
mice from infection (99). In addition, patients with IgA deficiency have been shown 
to have increased risk of developing gastrointestinal carcinomas (102, 103) and 
gastric adenocarcinoma patients have decreased production of gastric IgA antibodies 
(Quiding-Järbrink et al., submitted for publication). These studies show that a 
protective, albeit not necessarily essential, role for antibodies against H. pylori 
infection and H. pylori-associated diseases cannot be ruled out. Evaluation of H. 
pylori-specific mucosal IgA antibodies in the stomach of infected and immunized 
mice showed that only orally immunized mice had significantly increased levels of 
IgA antibodies compared to control infected mice (II). 
The ip immunization regimen with alum as adjuvant, which induces protection 
when used prophylactically (91) did not result in decreased H. pylori colonization 
after therapeutic immunization (II). It does not seem to be the parenteral 
immunization per se that only works prophylactically, because Sanchez et al. have 
shown that subcutaneous therapeutic immunization with antigens together with the 
cationic liposome DC -Choi as adjuvant can induce protection against H. pylori (148). 
However, T cells seemed to be important for the protection induced by alum because 
transfer of CD4+ T cells from immunized mice to otherwise immunodeficient ragl + 
recipients induced protection against H. pylori infection in these mice (91). 
Furthermore, we could show that prophylactic, but not therapeutic ip immunization, 
induced mucosal T cell responses (II) and this discrepancy could explain the 
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differences in protection after prophylactic and therapeutic ip immunization. One 
possible reason for the lack of protection against H. pylori after therapeutic ip 
immunization with alum as adjuvant could be the induction of fu nctional H. pylori-
specific CD4+CD25+ regulatory T cells (Treg) in the gastric mucosa (149, 150), which 
could have immunosuppressive effects on the immune responses against the H. 
pylori infection. Thus, it is tempting to speculate that expansion of Treg during an 
ongoing H. pylori infection suppresses the induction of immune responses that only 
oral therapeutic immunization with a strong mucosal adjuvant such as CT can 
overcome whereas the ip immunization with alum cannot. This suggests that 
different magnitudes of immune responses or possibly different immune 
mechanisms are required to provide protection against H. pylori infection after 
therapeutic compared to prophylactic immunization. 
The mechanisms for the protection induced by therapeutic immunization in our 
mouse model of H. pylori infection are still not fully understood. One possible model 
for how protection is induced against H. pylori following immunization and 
mediated by the immune system may be as follows: 
The immunostimulatory effect of CT used as adjuvant for oral immunization 
enhances uptake of the coadministered antigen in the intestine and stimulates 
antigen presentation (58, 60). The activated B and T cells will thereafter home to the 
gastric mucosa. Thus, the oral immunization with antigen and CT leads to increased 
antigen-specific B and T cell responses against the antigen in the stomach. Plasma 
cells will secrete H. pylori-specific IgA antibodies into the gastric lumen where they 
adhere to the mucus and prevent the bacterium from binding to the epithelial cells. 
The activated T cells, predominantly of the Thl type in the stomach, can secrete IFN-
y to activate tissue resident and recruited macrophages. The effector T cells or the 
activated macrophages could in turn influence the epithelial cells by cytokine 
secretion. Thus, the epithelial cells may be the "ultimate effector cell" and function as 
a bridge between the CD4+ T cells and H. pylori by affecting the bacterial colonization 
in a number of ways: 
O Secretion of defensins. Indeed, it has been shown that a-defensins (that act by 
damaging the bacterial cell wall) and factors involved in epithelial 
maintenance/defence are upregulated in H. pylori immunized and protected mice 
(151). 
0 Increased epithelial cell turnover (151). This may be disadvantageous for the 
colonization of H. pylori because the bacteria adhere to epithelial cells. 
O Alteration and/or increase of the mucin secretion (151,152). For example, changes 
in the viscosity of the mucus may impair the motility of H. pylori (153). In 
addition, a human gastric mucin has been shown to have antimicrobial activity 
against H. pylori (154). 
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Many other cell types and signals have also been suggested to be involved in 
diminishing or clearing the H. pylori infection. Inducible nitric oxide synthase (iNOS) 
is upregulated in the gastric mucosa of immunized and protected mice (141). 
However, mice lacking iNOS are equally well protected as wild-type mice, 
suggesting that NO is probably not involved in protection but may contribute to the 
inflammation (141). In addition, adipokines, e.g. cytokine-like molecules produced 
by mature adipocytes and some other cell types, have recently been implied as a link 
between the endocrine and immune system and such molecules have been found to 
be upregulated in vaccinated and protected mice (151, 155). One hypothesis of their 
function may be that they stimulate gastric T cells or epithelial cells. All together, the 
combination of many of these effector molecules and events may result in 
suppression of H. pylori colonization in the stomach of immunized mice. 
An important aim of these studies was to try to identify protective vaccine candidate 
antigens. Because HpaA has several properties of an optimal candidate antigen, e.g. 
it is surface located, immunogenic and present in all H. pylori strains but not in other 
species, we wanted to evaluate its contribution to H. pylori colonization and 
immunity (III). By infecting mice with the mouse adapted strain SSI or its isogenic 
mutant SS1(AhpaA) we could clearly demonstrate that HpaA is essential for H. pylori 
colonization in mice because only infection with the wild-type, but not the mutant, 
resulted in H. pylori colonized mice. 
However, the function of HpaA is still unknown. Although originally described to be 
an adhesin, our HpaA mutant displayed the same binding properties as the wild-
type strain for binding both to previously identified H. pylori binding 
glycosphingolipids and to gastric cell lines (Teneberg S, unpublished data, 19). It 
may therefore be possible that HpaA has a role unrelated to adhesion, e.g. HpaA 
may facilitate colonization of H. pylori i n the gastric mucosa. For example, hpaA is 
cotranscribed together with ompl8 and tig, which may suggest that their functions 
are related. The function of Ompl8 is unknown, but based on sequence homologies 
Tig has been suggested to be involved in peptide secretion and trafficking (27, 28). 
This, together with the fact that HpaA has been found to be present in high 
quantities in the inner membrane may suggest that HpaA also has a shuttle function. 
Notably, HpaA has been shown to directly stimulate and activate human DC in vitro 
(128) but it is not known through which receptor this activation is initiated. 
We next wanted to evaluate the capacity of H paA as a candidate vaccine antigen for 
therapeutic immunization against H. pylori in mice (IV). Indeed, we concluded that 
HpaA is a very promising candidate antigen, because oral therapeutic immunization 
of mice with this antigen together with CT resulted in dramatic decrease in bacterial 
load in the stomachs of H. pylori infected mice compared to in control infected mice. 
This effect was even stronger when mice were immunized with both HpaA and 
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urease together with CT. To the best of our knowledge, the reduction in bacterial 
load seen with this combination is comparable to or higher than any other antigen(s) 
used for oral therapeutic immunization against H. -pylori in mice (40, 89, 156). This 
would suggest that an optimal H. pylori vaccine should consist of a cocktail of a few 
H. pylori-specific antigens, which could induce additive or synergistic immune 
responses against H. pylori by targeting different essential components of the bacteria 
or different levels in the pathogenesis. However, whether this particular combination 
of HpaA and urease would work as efficiently for prophylactic immunization 
remains to be determined, since one study has shown that the optimal antigen 
combinations for induction of prophylactic protection are different from the 
therapeutic ones (148). For example, a bivalent prophylactic vaccine with urease 
combined with antigen e.g. AlpA or catalase, was optimal for inducing protection 
against a subsequent challenge. However, therapeutic immunization was most 
effective when using AlpA together with BabB. In contrast to our results (IV), 
Sanchez et al. showed that a therapeutic bivalent vaccine consisting of urease 
together with AlpA or BabB did not confer any stronger protection than the mice 
immunized with these antigens alone. On the other hand, they used another 
immunization regimen (subcutaneous immunization with DC Choi) and challenge 
strain than we did, which may account for the different results (148). 
However, identification of a candidate vaccine antigen is not enough for 
development of a human vaccine against H. pylori, because we and others have 
shown that the type of immunization (prophylactic vs therapeutic) (II, 88, 91), 
adjuvant-antigen combination (I, II, III) and timing of the immunizations (II, 52) all 
are important parameters that may affect the induction of mucosal immune 
responses against H. pylori. Indeed, the reason why clinical vaccine trials against H. 
pylori have so far failed is probably not due to the antigen used (e.g. urease and 
lysate), but rather to the fact that the mucosal adjuvants have not been able to induce 
sufficient protective immune responses against the coadministered antigens (78, 87). 
In conclusion, the results in this thesis suggest that an optimal therapeutic vaccine 
against H. pylori should be administered orally and include an effective mucosal 
adjuvant. The antigens in such a therapeutic vaccine should provide protection 
against different key pathogenic mechanisms, e.g. HpaA and urease. Our findings 
further suggest that the immunization should induce antigen-specific CD4+ T cell 
responses with a Thl profile (IFN-y and TNF-a) and probably also locally produced 
specific Ig A. 
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